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Background: Current treatment of ovarian cancer patients with chemotherapy leaves behind a residual tumor
which results in recurrent ovarian cancer within a short time frame. We have previously demonstrated that a single
short-term treatment of ovarian cancer cells with chemotherapy in vitro resulted in a cancer stem cell (CSC)-like
enriched residual population which generated significantly greater tumor burden compared to the tumor burden
generated by control untreated cells. In this report we looked at the mechanisms of the enrichment of CSC-like
residual cells in response to paclitaxel treatment.
Methods: The mechanism of survival of paclitaxel-treated residual cells at a growth inhibitory concentration of 50%
(GI50) was determined on isolated tumor cells from the ascites of recurrent ovarian cancer patients and HEY ovarian
cancer cell line by in vitro assays and in a mouse xenograft model.
Results: Treatment of isolated tumor cells from the ascites of ovarian cancer patients and HEY ovarian cancer cell
line with paclitaxel resulted in a CSC-like residual population which coincided with the activation of Janus activated
kinase 2 (JAK2) and signal transducer and activation of transcription 3 (STAT3) pathway in paclitaxel surviving cells.
Both paclitaxel-induced JAK2/STAT3 activation and CSC-like characteristics were inhibited by a low dose JAK2-specific
small molecule inhibitor CYT387 (1 μM) in vitro. Subsequent, in vivo transplantation of paclitaxel and CYT387-treated
HEY cells in mice resulted in a significantly reduced tumor burden compared to that seen with paclitaxel only-treated
transplanted cells. In vitro analysis of tumor xenografts at protein and mRNA levels demonstrated a loss of CSC-like
markers and CA125 expression in paclitaxel and CYT387-treated cell-derived xenografts, compared to paclitaxel
only-treated cell-derived xenografts. These results were consistent with significantly reduced activation of JAK2
and STAT3 in paclitaxel and CYT387-treated cell-derived xenografts compared to paclitaxel only-treated cell
derived xenografts.
Conclusions: This proof of principle study demonstrates that inhibition of the JAK2/STAT3 pathway by the addition of
CYT387 suppresses the ‘stemness’ profile in chemotherapy-treated residual cells in vitro, which is replicated in vivo,
leading to a reduced tumor burden. These findings have important implications for ovarian cancer patients who
are treated with taxane and/or platinum-based therapies.
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Current treatment for advanced-stage ovarian cancer
patients consists of aggressive surgery followed by che-
motherapy to eradicate the residual disease [1,2]. Post-
operatively, all women, except those diagnosed with
Stage 1 well differentiated tumors are given platinum
(cisplatin or carboplatin) and taxane (paclitaxel)-based
chemotherapies, resulting in initial remission in up to
80% of patients. Unfortunately, the majority of these
patients relapse within two years, resulting in a 5-year
survival rate of only 27% [3]. This low survival rate is
largely due to the presence of chemotherapy-resistant
residual tumor cells which have the capacity to with-
stand the cytotoxic effects of therapies and repopulate,
leading to recurrence [4]. Previous studies on the mecha-
nisms underlying the failure of taxane and cisplatin-based
chemotherapy have implicated enhanced expression of
multidrug transporters [5], involvement of anti-apoptotic
pathways [6], mutations in the p53 pathway [7,8], in-
creased glutathione and metallothionein levels [9], altered
expression of tubulin binding proteins [10], expression of
taxane metabolizing proteins, altered cell signaling result-
ing in reduced apoptosis [11] and epithelial mesenchymal
transition (EMT) [12-14].
Ovarian cancer is a disease commonly complicated by
the presence of ascites in the abdominal cavity [3,15].
As the disease progresses tumor cells are shed in the as-
cites by the rupture of the primary tumor surface [2].
Aggregates of tumor cells commonly known as ‘spheroids’
float freely in an anchorage independent condition in
ascites [16-19]. This transceolomic route of ovarian
cancer metastasis has been suggested due to the devel-
opment of ovarian cells from the coelomic mesothelium
during embryogenesis [20]. The attachment of spher-
oids to the peritoneum has been shown to be facilitated
by cell surface proteins such as CD44, collagen 1 and β1
integrin which facilitate adhesion to the mesothelial
cells lining the peritoneal cavity [21,22]. Once attached
to the peritoneal surface, cancer cells proliferate and
invade the mesothelium (outer layer of the peritoneal
membrane) [23]. It is thought that this process of seeding
of the peritoneum is directly associated with the production
of ascites, evidenced by the reduction of ascites volume
when patients undergo debulking surgery or chemotherapy
treatment that removes the majority of residual macro-
scopic disease [3,15]. Along with transcoelomic metastatic
tumors, extensive seeding of cancer cells on various ab-
dominal organs such as the colon, uterus and omentum
is commonly observed in the late-stage disease [2].
The presence of cancer stem cells (CSCs) in the ascites
of ovarian cancer patients was demonstrated nearly eight
years ago [24]. In recent studies, the presence of CSCs
in ovarian cancer has been shown by using side popula-
tion sorting or by sorting cells using specific cell surfacemarkers and intracellular expression of proteins (CD44,
My88, CD133, CD117, CD24, ALDH1) commonly con-
sidered to be CSC markers [25-30]. CSCs have been
demonstrated to produce greater tumor burden and to
be resistant to chemotherapy [31,32]. In recent studies
we and others have shown recurrent ovarian tumors to
be enriched with CSCs and mediators of pathways that
regulate CSCs, suggesting that CSCs may contribute to
the development of recurrence [33,34].
The JAK2/STAT3 pathway mediates the effects of
many growth factors and cytokines by regulating the ex-
pression of downstream gene expression [35]. In normal
cells, the JAK2/STAT3 pathway is transiently activated
in response to specific growth factors and cytokines
(IL6, GCSF, LIF, EGF, etc.). However, in cancer cells, in-
cluding breast, ovarian and prostate, the JAK2/STAT3
pathway is constitutively active in the majority of cases
[36,37]. We and others have previously shown nuclear
localization of activated phosphorylated STAT3 in more
than 70% of high-grade serous ovarian cancer, where it
was associated with decreased survival [36,38]. This
pathway has been linked with cancer cell survival and
chemoresistance in ovarian, as well as number of other
solid cancers [13,39,40].
CYT387 is a specific JAK2 inhibitor which is in clinical
development as treatment for a diverse range of diseases,
including myelofibrosis [41] and myeloma [42]. CYT387
demonstrated efficacy in a JAK2V617F mutation-associated
animal model where it inhibited constitutively activated
JAK2 associated STAT3 function by neutralizing IL-6 by a
negative feed-back inhibition [41]. The compound showed
a negligible effect on the metabolism of other agents and is
unlikely to participate in metabolic drug-drug interactions
[41]. Preclinical analysis has shown that CYT387 was
well tolerated when administered to mice orally at doses
up to 50 mg/kg of body weight, with no sign of overt
toxicity [41].
In this study, we demonstrate that a short-term single
exposure of CYT387 in addition to paclitaxel reduces the
CSC-like characteristics and activation of JAK2/STAT3
pathway promoted by paclitaxel in residual cells in vitro.
The in vitro suppression of CSC-like characteristics and
activation of JAK2/STAT3 pathway by CYT387 is mim-
icked in in vivo mouse xenografts with a reduced tumor
burden. These data emphasize the need to explore further
the effect of CYT387 in combination with chemotherapy
in pre-clinical ovarian cancer models.
Methods
Cell line
The human ovarian HEY cell line was derived from a
peritoneal deposit of a patient diagnosed with papillary
cystadenocarcinoma of the ovary [43]. The cell line was
grown as described previously [44].
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Polyclonal antibody against phosphorylated (Tyr-705)
STAT3 (P-STAT3), total STAT3 (T-STAT3), phosphory-
lated (Tyr-1007/1008) JAK2 (P-JAK2), total JAK2 (T-JAK2)
and GAPDH were obtained from Cell Signalling Technol-
ogy (Beverly, MA, USA). Antibodies against cytokeratin
7 (cyt7), Ki67, CA125, E-cadherin, vimentin, Oct4 and
CD117 (c-Kit) used for immunohistochemistry were ob-
tained from Ventana (Roche, Arizona, USA). CYT387
was obtained from Gilead Sciences (CA, USA).
Patients
Human ethics statement
Ascites was collected from patients diagnosed with
Stages IIa-IV serous ovarian carcinoma and adenocar-
cinoma Not Otherwise Specified (NOS) (Table 1), after
obtaining written informed consent under protocols ap-
proved by the Human Research and Ethics Committee
(HREC approval # 09/09) of The Royal Women’s Hospital,
Melbourne, Australia. HREC approval #09/09 also ob-
tained consent from participants to publish the results
from this study provided anonymity of patients is main-
tained at all times.
The histopathological diagnosis, including tumor grades
and stage was determined by independent staff patholo-
gists as part of the clinical diagnosis (Table 1). Ascites was
collected as they were received by the laboratory. For col-
lection of ascites preference was given to samples obtained
from patients diagnosed with serous ovarian cancer. How-
ever, to meet the experimental demand samples from
three patients diagnosed with adenocarcinomas NOS were
also included. Ascites was collected from patients at the
time of recurrence. Patients in this group were not all
treated identically and had previously received combina-
tions of chemotherapy consisting of paclitaxel, carboplatin
and other drugs such as doxorubicin, gemcitabine, do-
cetaxel, cyclophosphamide and topotecan after each
recurrent episode (Table 1).
Preparation of tumor cells from ascites of ovarian cancer
patients
Tumor cells from ascites were isolated as described previ-
ously [34]. Briefly, 500 ml of ascites was used to collect
tumor cells. The ascites cells were seeded on low attach-
ment plates (Corning Incorporated, NY) in MCDB:
DMEM (50:50) growth medium supplemented with fetal
bovine serum (10%), glutamine (2 mM) and penicillin/
streptomycin (2 mM) (Life Technologies, CA, USA) after
removal of the red blood cells by hypotonic shock using
sterile MilliQ water as described previously [34]. Cells
were maintained at 37°C in the presence of 5% CO2 and
tumor cells floating as non-adherent population were col-
lected after 2–3 days, and screened for CA125, EpCAM,
cytokeratin 7 (CK7) and fibroblast surface protein (FSP)by Flow Cytometry to assess their purity. Cells were
passaged weekly and experiments were performed within
1–2 passages.
Treatment of HEY and isolated tumor cells with paclitaxel,
CYT387 or combination of both
Isolated ascites tumor cells and ovarian cancer cell line
HEY were treated with paclitaxel concentrations at which
50% growth inhibition was obtained (GI50 ~ 6 ng/ml for
ascites tumor cells and 1 ng/ml for HEY cells for three
days) [45]. For CYT387 treatment, cells were screened
for the response to different concentrations of CYT387
in HEY cells. The concentration of CYT387 that gave
optimum inhibition of the active (phosphorylated) JAK2/
STAT3 pathway by Western blot in response to paclitaxel
in HEY cells was ~1 μM, and as such, 1 μM CYT387 was
used throughout the study. For combination treatment,
ascites-derived tumor cells were treated with 6 ng/ml of
paclitaxel and 1 μM of CYT387, while the HEY cells were
treated with 1 ng/ml of paclitaxel and 1 μM of CYT387.
Treatment was performed for three days.
Immunofluorescence analysis
Immunofluorescence analysis of β-tubulin, ERCC1,
EPCAM, CD117, NANOG, Oct-4, P-STAT3, T-STAT3,
P-JAK2 and T-JAK2 was performed as described previ-
ously [34]. Images were captured by the photo multiplier
tube (PMT) using the Leica TCS SP2 laser, and viewed on
a HP workstation using the Leica microsystems TCS SP2
software. The mean fluorescence intensity was quantified
using Cell-R software (Olympus Soft Imaging Solution).
When calculating mean fluorescence intensities a com-
parative field of view with equal number of cells was
chosen for each analysis to compensate for the disparity
between cell numbers in the wells containing treated
and untreated cells. As such, the calculations were per-
formed on equal number of cells.
RNA extraction and Real Time-PCR (q-PCR)
Solid tumors derived from mice inoculated with HEY
cells were homogenised using PowerLyzer™ 24 (MO BIO
Laboratories Inc, Carlsbad CA, United States) according
to manufacturer’s instruction. RNA was extracted from
the homogenised xenograft and cDNA synthesised as
described previously [34]. Quantitative determination of
mRNA levels of various genes was performed in tripli-
cate using SYBR green (Applied Biosystems, Australia)
as described previously [34]. The primers for Oct-4,
NANOG, CD44, CD117, and EpCAM have been de-
scribed previously [14].
SDS-PAGE and Western blot analysis
SDS-PAGE and Western blot was performed on cell ly-
sates by the methods described previously [14]. Protein
Table 1 Description of the patients recruited for the study
Samples Stage Grade Treatment cycles Age Overall survival
Ascites 1 IIIc High Grade Serous Carboplatin and Paclitaxel 6 cycle 39 years at diagnosis 3 years and 7 months
Doxorubicin Pegylated Liposomal 9 cycles
Gemcitabine and Carboplatin 3 cycles
Paclitaxel (12 treatments in cycle 1, 3
treatments in cycles 3 through to 9)
Ascites 2 IIa High Grade Serous Carboplatin 5 cycles 78 years at diagnosis 6 months
Ascites 3 Unknown Not Graded Carboplatin and Paclitaxel 4 cycles 59 years at diagnosis 5 months as of 20/11/2012
Ascites 4 Unknown Adenocarcinoma NOS Carboplatin and Paclitaxel 6 cycles 75 years at diagnosis 1 year 8 months
Tamoxifen 2 cycles
Doxorubicin Pegylated Liposomal 4 cycles
Ascites 5 IIc High Grade Serous Carboplatin and Paclitaxel 4 cycles,
Topotecan 1 cycle
64 years at diagnosis 5 months
Ascites 6 IIIc High Grade Serous Carboplatin and Paclitaxel 6 cycles 52 years at diagnosis 2 years 5 months
AMG-386 182 Trial 8 cycles
Paclitaxel 3 cycles
Paragon Trial 2 cycles
Carboplatin single agent 3 cycles
Cyclophosphamide 2 cycles
Ascites 7 IIIc High Grade Serous Carboplatin and Paclitaxel 9 cycles 59 years at diagnosis 2 years 6 months
Cisplatin 4 cycles
Cyclophosphamide 2 cycles
Ascites 8 IV Adenocarcinoma NOS Carboplatin and Paclitaxel 6 cycles 67 years at diagnosis 2 years 6 months
Gemcitabine and Carboplatin 6 cycles
Ascites 9 Unknown Adenocarcinoma NOS Cyclophosphamide 3 cycles 2 years 8 months
Carboplatin and Paclitaxel 6 cycles 65 years at diagnosis
MORAb Trial 9 cycles
Doxorubicin Pegylated Liposomal 3 cycles
Ascites 10 IIIc High Grade Serous Doxorubicin Pegylated Liposomal 3 cycles 55 years 5 years 5 months
ICON 7 Trial 18 cycles
ICON 6 Trial 6 cycles
Paragon Trial 1 cycle
Paclitaxel 6 cycles
Ascites 11 IIIc High Grade Serous Hormonal Therapy Tamoxifen 69 years at diagnosis 7 years 11 months
Topotecan Hydrochloride 2 cycles
Carboplatin and Paclitaxel 6 cycles
Carboplatin single agent 6 cycles
Gemcitabine and Carboplatin 6 cycles
Carboplatin single agent 6 cycles
Cyclophosphamide 6 cycles
Doxorubicin Pegylated Liposomal 4 cycles
Paclitaxel 3 cycles
Ascites 12 IIIc High Grade Serous Doxorubicin Pegylated Liposomal 3 cycles
Carboplatin and Paclitaxel 6 cycles
59 years at diagnosis 2 years 11 months as of
21/05/2013
Gemcitabine and Carboplatin 6 cycles
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Table 1 Description of the patients recruited for the study (Continued)
Ascites 13 IIIc High Grade Serous Doxorubicin Pegylated Liposomal 4 cycles 53 years at diagnosis 2 years 11 months as of
21/05/2013
Carboplatin and Paclitaxel 6 cycles
AMG-386 182 9 cycles
Paclitaxel 6 cycles
Cyclophosphamide 2 cycles
Topotecan 2 cycles
Ascites 14 IV High Grade Serous Carboplatin 1 cycle 46 years at diagnosis 2 years 6 months as of
13/08/2013
Carboplatin and Paclitaxel 6 cycles
Ascites 15 IIIc Not Graded Carboplatin 5 cycles 76 years at diagnosis 1 year and 8 months
Cyclophosphamide 7 cycles
Paragon Trial 3 cycles
NOS, Not Otherwise Specified.
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Restore Western blot Stripping Buffer (Thermo Scientific,
MA, USA) and re-probing the membrane with β-actin
primary antibody (Sigma-Aldrich, Sydney, Australia).
3[H]-Thymidine assay
3[H]-Thymidine uptake assay as a measure of cell prolifer-
ation was performed as described previously [34]. Briefly,
1×105 HEY cells or ascites-derived tumor cells untreated
or treated with paclitaxel or CYT387 + paclitaxel were
seeded in triplicate on 24 well plates. After 3 days, 0.5 μCi
of [3H] thymidine was added to each well, and cells were
incubated at 37°C for an additional 16 h. Cells were
washed with PBS, harvested and lysed in 1% Triton and
incorporation of [3H] thymidine was measured by liquid
scintillation counting (Hidex 300SL, LKB Instruments,
Australia).
Animal studies
Animal ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of the
Laboratory Animals of the National Health and Medical
Research Council of Australia. The experimental protocol
was approved by the Ludwig Institute/Department of
Surgery, Royal Melbourne Hospital and University of
Melbourne’s Animal Ethics Committee (Project-006/11),
and was endorsed by the Research and Ethics Committee
of Royal Women’s Hospital Melbourne, Australia.
Animal experiments
The animal experiments were performed as described
previously [45]. Briefly, female Balb/c nu/nu mice (age,
6–8 weeks) were obtained from the Animal Resources
Centre, Western Australia. Animals were housed in a
standard pathogen-free environment with access to
food and water. HEY cells were treated with paclitaxel(1 ng/ml) or CYT387 (1 μM) or paclitaxel (1 ng/ml)
plus CYT387 (1 μM) as described previously. 5×106
cells surviving treatments after three days were injected
intraperitoneally (ip) in nude mice. Mice were inspected
weekly and tumor progression was monitored based on
overall health and body weight until one of the pre-
determined endpoints was reached. Endpoint criteria
included loss of body weight exceeding 20% of initial
body weight and general pattern of diminished well-
being such as reduced movement and lethargy resulting
from lack of interest in daily activities. Mice were eutha-
nized and organs (liver, stomach, lungs, gastrointestinal
tract, pancreas, uterus, skeletal muscle, colon, kidney,
peritoneum, ovaries and spleen) and solid tumors were
collected for further examination. Metastatic develop-
ment was documented by a Royal Women’s Hospital
pathologist according to histological examination (H & E
staining) of the organs.Immunohistochemistry of mouse tumors
For immunohistochemistry, formalin fixed, paraffin em-
bedded 4 μm sections of the xenografts were stained using
a Ventana Benchmark Immunostainer (Ventana Medical
Systems, Inc, Arizona, USA) previously [45]. Immunohis-
tochemistry images were taken using Axioskop 2 micro-
scope, captured using a Nikon DXM1200C digital camera
and processed using NIS-Elements F3.0 software. Images
were scored independently by four reviewers blind to the
molecular data as previously described [46].Statistical analysis
Data are presented as mean ± SEM. Treatment groups
were compared with the control group using one way-
ANOVA and Dunnett’s Multiple Comparison post-tests.
A probability level of p < 0.05 was adopted throughout
to determine statistical significance.
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Treatment of isolated tumor cells with paclitaxel resulted
in the enhanced expression of ERCC1 and β-tubulin-III
Tumor cells from ascites were isolated as described previ-
ously [34]. The expression of ERCC1 and β-tubulin III
were analysed by immunofluorescence staining in isolated
tumor cells from ascites (control) and its paclitaxel-treated
(6 ng/ml for 3 days) counterpart. In three ascites samples
(Ascites 1–3, Table 1), very few control cells displayed
ERCC1 staining which was confined mainly within the
nuclear envelope (Figure 1). Cells from the same ascites
samples treated with paclitaxel demonstrated a signifi-
cantly higher number of ERCC1 stained cells and the
scattered staining was seen in the nucleus as well as the
cytoplasm (Figure 1). A similar enhancement in staining
was observed for β-tubulin III, with paclitaxel surviving
cells showing significantly enhanced staining when com-
pared to their matched control cells (Figure 1). Quantita-
tive measurement of three independent patient samples
demonstrated a significant enhancement of β-tubulin III
and ERCC1 staining in cancer cells surviving paclitaxel
treatment in vitro, compared to their matched control
counterparts (Figure 1).
Paclitaxel treatment enhanced the expression of CSC
markers in ascites-derived isolated tumor cells
Isolated tumor cells from the ascites of recurrent ovarian
cancer patients (Ascites 3–5, Table 1) were subjected to
paclitaxel treatment in vitro (6 ng/ml over three days).
After three days of treatment, paclitaxel surviving tumor
cells were analysed for the expression of CSC markersFigure 1 Increased expression of β-tubulin III and ERCC1 in ascites-de
immunolocalisation of β-tubulin III and ERCC1 in ascites-derived tumor cell
(green) and rabbit polyclonal (red) antibodies as described in the Methods
Alexa 590 (red) fluorescent labelled antibodies while nuclear staining was v
independent experiments from three independent patient samples. The m
using Cell-R software. Significant variations between the groups are indicatusing immunofluorescence and compared with their
control untreated counterparts (Figure 2). Staining of
EpCAM and CD117 were confined mostly to cell mem-
brane, while the staining of embryonic stem cell markers
NANOG and Oct4 were localised both in the cytoplasm
and nucleus (Figure 2). With paclitaxel treatment greater
nuclear staining of NANOG and Oct4 were observed
compared to control untreated cells (Figure 2). Quanti-
tative measurements of CSC markers examined by im-
munofluorescence imaging revealed a significant
enhanced staining of CSC markers EpCAM, CD117 and
the embryonic stem cell markers Oct4 and NANOG,
suggesting that the paclitaxel surviving population were
enriched for CSC-like markers (Figure 2).
In order to determine if the expression of CSCs as de-
duced by immunofluorescence was consistent at mRNA
level q-PCR was performed on isolated ascites cells
treated with and without paclitaxel (Ascites 4, 5, 7 and
9, Table 1) (Additional file 1: Figure S1). The expression
of CD117, Oct4 and JAGGED was significantly up in
paclitaxel-treated ascites tumor cells, while there was a
trend in the increased expression of EpCAM, CD44 and
NANOG but it was not significant compared to un-
treated control.
Paclitaxel treatment activated the JAK2/STAT3 pathway in
ascites-derived tumor cells
Isolated ascites-derived tumor cells from four patients
(Ascites 5, 6, 7 and 8 Table 1) were treated with pacli-
taxel and the activation of JAK2 (Tyr1007/1008) and
STAT3 (Tyr-705) were analysed by immunofluorescence.rived tumor cells in response to paclitaxel. Expression and
s was evaluated by immunofluorescence using mouse monoclonal
. Cellular staining was visualized using secondary Alexa 488 (green) and
isualized using DAPI (blue) staining. Images are representative of three
ean fluorescence intensity of β-tubulin III and ERCC1 was quantified
ed by *P < 0.05. Magnification 200×; scale bar = 10 μM.
Figure 2 Increased expressions of CSC and embryonic stem cell markers in ascites- derived tumor cells in response to paclitaxel.
Expression and localisation of EpCAM, CD117, Oct4 and NANOG in ascites-derived tumor cells in response to paclitaxel treatment was evaluated
by immunofluorescence as described in Figure 1. Images are representative of three independent experiments from three independent patient
ascites samples. The mean fluorescence intensity of CSC markers CD117, EpCAM and the embryonic stem cell markers NANOG and Oct4 expression in
ascites-derived tumor cells was quantified using Cell-R software. Significant variations between the groups are indicated by *P < 0.05. Magnification
200×; scale bar = 10 μM.
Figure 3 Expression and localisation of P-JAK2 and T-JAK2 in ascites-derived tumor cells in response to paclitaxel treatment. The images
were evaluated as described in Figure 1. Images are representative of four independent experiments from four patient samples. The mean fluorescence
intensity of P-JAK2 and T-JAK2 was quantified using Cell-R software. Significant intergroup variations are indicated by ***P < 0.001. Magnification 200×;
scale bar = 10 μM.
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Figure 4 Expression and localisation of P-STAT3 and T-STAT3 in ascites-derived tumor cells in response to paclitaxel treatment. The images
were evaluated as described in Figure 1. Images are representative of four independent experiments from four patient samples. The mean fluorescence
intensity of P-STAT3 and T-STAT3 was quantified using Cell-R software. Significant intergroup variations are indicated by ***P < 0.001. Magnification
200×; scale bar = 10 μM.
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ation of JAK2 (P-JAK2) (Figure 3) and downstream STAT3
(P-STAT3) (Figure 4) in paclitaxel surviving cells, com-
pared to their matched control counterparts. The expres-
sion of P-JAK2 in treated cells was mainly membrane
bound and cytoplasmic. The expression of P-STAT3 was
seen both in nucleus and cytoplasm of the treated cells.
In all ascites samples tested, no significant difference in
the level of total JAK2 (T-JAK2) and STAT3 (T-STAT3)
between the control and paclitaxel surviving cells could
be deduced by immunofluorescence (Figures 3 and 4).
Paclitaxel treatment activated the JAK2/STAT3 pathway in
chemotherapy surviving HEY cells; CYT387 inhibited
paclitaxel-induced JAK2/STAT3 activation
Consistent with the ascites-derived tumor cells, treat-
ment with paclitaxel resulted in the activation of the
JAK2/STAT3 pathway in the ovarian cancer HEY cell
line, resulting in a marked increase of both phosphory-
lated αSTAT3 (~86 kDa) and βSTAT3 (79 kDa) at two
and three days post-treatment by Western blot (Figure 5).Figure 5 Activation of STAT3 in response to paclitaxel treatment in H
48 and 72 hours. Cell lysates were prepared and Western blot was perform
by probing the membranes for GAPDH. Results are representative of threeThis observation was confirmed by immunofluorescence
which demonstrated significant enhancement in the level
of phosphorylated JAK2 (Tyr-1007/1008) and downstream
STAT3 (Tyr-705) compared to control untreated cells
(Figure 6A). Both P-JAK2 and P-STAT3 in paclitaxel-
treated cells were found to be localised in the nucleus as
well as cytoplasm of the paclitaxel-treated cells (Figure 6A).
The expression of T-JAK2 and T-STAT3 which was
localised mostly in the cytoplasm under the same ex-
perimental conditions remained unchanged (Figure 6B).
Paclitaxel-induced activation of JAK2 and downstream
STAT3 were inhibited by CYT387, a potent small mol-
ecule JAK2 inhibitor (Figure 6A). Optimal inhibition of
paclitaxel-induced JAK2/STAT3 activity was observed at
1 μM CYT387, which was subsequently used in all further
experiments. The addition of CYT387 to paclitaxel-treated
cells resulted in a significant reduction of P-STAT3 and
P-JAK2 expression in HEY cells, compared to residual cells
surviving paclitaxel only treatment (Figure 6A). However,
the expression of total JAK2 and STAT3 expression
remained unchanged in all treatment groups (Figure 6B).EY cells. HEY cells were treated with paclitaxel (1 ng/ml) for 6, 12, 24,
ed as described in the Methods. Total protein loading was determined
independent experiments.
Figure 6 (See legend on next page.)
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Figure 6 Expression of phospho and total JAK2 and STAT3 in control, paclitaxel and paclitaxel plus CYT387-treated HEY cells.
(A) Expression and immunolocalisation of phospho (P)-JAK2 (Tyr-1007/1008) and phospho (P)-STAT3 (Tyr-705) in control, paclitaxel, CYT387 and
combination of both treatments in HEY cell line was evaluated by immunofluorescence. Three independent experiments were performed in
triplicate. The mean fluorescence intensity was quantified using Cell-R software. Significant variations between the groups are indicated by
*P<0.05, *** P < 0.001. (B) The expression of total (T)-JAK2 and total (T)-STAT3 was evaluated and quantified as described in Figure 6A.
Magnification 200x; scale bar = 10 μM.
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activation in ascites-derived tumor cells
Consistent with HEY cell line, addition of CYT387 re-
sulted in the inhibition of phosphorylation of JAK2 and
STAT3 in paclitaxel-induced ascites-derived tumor cells
(Ascites 9–11, Table 1), while the expression of T-JAK2
and T-STAT3 remained unchanged (Figure 7A and B).CYT387 treatment significantly reduced the CSC-like trait
associated with paclitaxel treatment in HEY cells and
ascites-derived tumor cells
We have previously shown the existence of CSC-like
phenotypes in ovarian cancer cell lines, including the
HEY cell line, primary and ascites-derived ovarian tumor
cells isolated from ovarian cancer patients in response to
cisplatin and paclitaxel treatments [14,32,45]. In order to
assess if this phenomenon can be reversed by the inhib-
ition of JAK2/STAT3 pathway by CYT387 in the presence
of paclitaxel, we assessed the CSC-like profile of paclitaxel
and CYT387-treated HEY cells at the mRNA level using
qRT-PCR and compared that to control untreated as
well as paclitaxel or CYT387 treatments alone (Figure 8A).
Paclitaxel-treated HEY cells displayed significantly
enhanced mRNA expression of CSC markers CD44,
CD117, EpCAM and the embryonic stem cells markers
Oct4 compared to control untreated or CYT387-treated
cells (Figure 8A). However, this enhancement of CSC-like
marker profile in response to paclitaxel treatment was
abolished with the addition of CYT387, resulting in a
significant reduction in the mRNA levels of Oct4 and
EpCAM, while the mRNA expression of CD117 and CD44
was decreased but it was not significant (Figure 8A).
Similar to the results obtained with the HEY cell line,
paclitaxel treatment of ascites derived tumor cells (As-
cites 13–15) resulted in the significant enhancement of
all tested CSC markers compared to their matched
counterparts that did not receive paclitaxel treatment
(Figure 8B-C). Treatment with only CYT387 did not
result in any change in the expression of the CSC
markers compared to the matched control counter-
parts (Figure 8B-C). However, the addition of CYT387
with paclitaxel to ascites-derived tumor cells demon-
strated significant down regulation of CSC and embryonic
stem cell markers when compared to the matched coun-
terparts surviving paclitaxel only treatment (Figure 8B-C).The addition of CYT387 significantly enhanced the
sensitivity of HEY cells and ascites-derived tumor cells to
paclitaxel treatment
The growth pattern of HEYcells and ascites derived tumor
cells (n = 3) in the presence of paclitaxel, CYT387 or pacli-
taxel plus CYT387 was determined by 3[H]-thymidine up-
take assay. The HEY cell line and ascites-derived tumor
cells were treated with ~GI50 concentration of paclitaxel
(1 ng/ml for HEY cells and 4-6 ng/ml for ascites tumor
cells) and 1 μM concentration of CYT387, to determine if
the combination of paclitaxel and CYT387 had an effect
on the proliferation of cells compared to that obtained
with the paclitaxel treatment alone (Figure 9A). The
addition of CYT387 (1 μM) in the presence of paclitaxel
sensitized HEY cells to paclitaxel treatment by significantly
reducing the proliferation of cells by a further ~40% com-
pared to paclitaxel only treated cells (Figure 9A). Similarly,
addition of CYT387 (1 μM) sensitised the isolated ascites-
derived tumor cells to paclitaxel by significantly reducing
cell proliferation by approximately ~50-90% further than
that obtained by paclitaxel alone treatment (Ascites 13–
15, Table 1) (Figure 9B). Even though the proliferation rate
of the three tumor populations derived from three patients
was significantly different, CYT387 was able to sensitise
all three ascites-derived tumor populations to paclitaxel
(Figure 9B).
Combination of paclitaxel and CYT387 treatment of HEY
cells generated lower tumor burden in mice compared to
tumor burden derived from paclitaxel-treated cells
The effect of the addition of CYT387 in conjunction with
paclitaxel treatment was tested in in vivo mouse intraperi-
toneal (ip) HEY xenograft model used previously [45].
Mice (n = 5) injected with control untreated HEY cells de-
veloped solid tumors in the form of 3–4 small lesions
(<0.5 cm3) in the peritoneum within six weeks. The aver-
age weight of the debulked tumors from the five control
mice injected with untreated HEY cells weighed approxi-
mately 4.8% ± 2.3 of the total bodyweight (Figure 10). In
contrast, mice injected with the same number (5×106) of
paclitaxel-surviving HEY cells produced a significantly lar-
ger tumor burden within the same time period, with the
average tumors weighing ~ 13.32% ± 2 of the total body
weight (Figure 10). On the other hand, tumors in mice
injected with CYT387 plus paclitaxel treated cells weighed
on average 4% ± 1.4 of the total mouse body weight
Figure 7 (See legend on next page.)
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Figure 7 Expression and localisation of phosphorylated and total JAK2 and STAT3 in control, paclitaxel and paclitaxel plus CYT387-treated
ascites derived tumor cells. (A) Expression and immunolocalisation of phospho (P)-JAK2 (Tyr-1007/1008) and total (T)-JAK2 in control, paclitaxel,
CYT387 and combination of both treatments in ascites-derived tumor cells was evaluated as described in Figure 6A. Images are representative of three
independent experiments performed in triplicate using three independent patient samples. Significant variations between the groups are indicated by
**P<0.01, ***P < 0.001. (B) The expression of phospho (P)-STAT3 and total (T)-STAT3 was evaluated and quantified as described in Figure 6A. Significant
variations between the groups are indicated by **P<0.01, ***P < 0.001. Magnification 200x; scale bar = 10 μM.
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with CYT387 only treated HEY cells was ~ 3.5% ± 1.3 of
the total body weight. In short, no significant difference in
the tumor burden was observed between groups of mice
injected with control untreated HEY cells or HEY cells
treated with CYT387 (Figure 10). On the other hand, sig-
nificantly lower tumor burden was observed in mice
injected with HEY cells treated with a combination of pac-
litaxel and CYT387 versus mice injected with cells treated
with paclitaxel alone (Figure 10). These results suggest
that CYT387 in combination with paclitaxel reduces the
tumor burden induced by paclitaxel only treatment,
however, CYT387 on its own had no significant effect in
reducing the tumor burden compared to control HEY
cells-derived tumor burden.
CYT387 in combination with paclitaxel significantly
reduced CSC marker expression at the protein and mRNA
levels in xenografts compared to xenografts derived from
paclitaxel only treated cells
Debulked mouse tumors from mice inoculated with con-
trol, paclitaxel, CYT387 or paclitaxel plus CYT387 treated
HEY cells were analysed using immunohistochemistry.
Mouse tumors displayed positive staining for CK7 in
all treatment-derived tumors cells (Additional file 2:
Figure S2). In addition, positive staining for the prolif-
erative marker Ki67 was also shown, with significantly
reduced staining observed in tumors derived from pac-
litaxel plus CYT387 treatment surviving HEY cell-
derived xenografts compared to paclitaxel only treated
group (Additional file 2: Figure S2). We also performed
immunohistochemistry analysis of the active (phos-
phorylated) and total JAK2 and STAT3 levels in mouse
xenografts in the all four groups. Paclitaxel treatment
derived tumors displayed significantly enhanced stain-
ing for both P-JAK2 and P-STAT3 compared to tumors
derived from untreated or CYT387-treated HEY cells
derived tumours (Figure 11A-B). On the other hand,
tumors derived from HEY cells treated with paclitaxel
plus CYT387 displayed significantly decreased staining
for P-JAK2 and P-STAT3 compared to tumors derived
from paclitaxel-treated cells, but expressed P-JAK2 and P-
STAT3 at the same level as tumors derived from control
untreated or CYT387-treated HEY cells (Figure 11A-B).
The expression of T-JAK2 and T-STAT3 remained un-
changed in control and treatment groups.Coinciding with the activation of the JAK2/STAT3 path-
way, immunohistochemistry analysis of mouse tumors for
the CSC marker CD117 (c-kit), the embryonic stem cell
marker Oct4 and the ovarian cancer marker CA125 re-
vealed significantly enhanced staining in xenografts de-
rived from cells surviving paclitaxel treatment compared
to control untreated cells (Figure 12A-B). The expression
of CD117, Oct4 and CA125 were reduced significantly in
CYT387 plus paclitaxel treated cells-derived xenografts
compared to paclitaxel only treated cells-derived xeno-
grafts, and was more comparable to xenografts derived
from control untreated or CYT387-treated cells xeno-
grafts (Figure 12A-B). To determine if the changes in
CSC markers seen in mouse xenografts derived from
paclitaxel-treated and paclitaxel plus CYT387-treated
HEY cells were consistent at the mRNA level; q-PCR was
performed on cDNA prepared from RNA extracted from
these tumors. Compared to xenografts derived from con-
trol untreated HEY cells, tumors derived from paclitaxel
surviving cells showed significant enhancement of mRNA
expression of CD117 and EpCAM (Figure 12C). Although
paclitaxel treatment derived tumors showed significant
enhancement of Oct4 at the protein level, and an appar-
ent increase at the mRNA level, this enhancement was not
statistically significant. An assessment of total STAT3
expression as the mRNA level showed no difference in
STAT3 between all treatment groups.
CYT387 in combination with paclitaxel does not reduce
tumor invasion in mice
The tumor infiltration pattern within the peritoneal cavity
in response to paclitaxel, CYT387, paclitaxel plus CYT387
was assessed using the H&E staining. In line with our
previous study [45], sections of mouse organs (pancreas,
liver, intestine, colon, and kidney) displayed infiltrating
tumors with epithelial morphology. Although the addition
of CYT387 with paclitaxel resulted in the significant re-
duction of tumor burden, an observation using a mini-
mum of three mice in all treatment groups revealed
no difference in the invasion pattern in all treatment
regimens (images for pancreas and liver presented in
Additional file 3: Figure S3.
Discussion and conclusions
Despite advances in cancer treatment, a diagnosis of
ovarian cancer is associated with a five year survival
Figure 8 (See legend on next page.)
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Figure 8 Expression of CSC markers in control, paclitaxel, CYT387 and paclitaxel plus CYT387-treated HEY cells and ascites derived
tumor cells. (A) RNA from control and treated HEY cells was extracted, cDNA was prepared and qPCR for EpCAM, CD44, CD117 and Oct4 was
performed as described in the Methods section. The resultant mRNA levels were normalized to 18S mRNA. The experiment was performed using
four independent samples in triplicate. Significant intergroup variations are indicated by *P <0.05, **P<0.01, ***P < 0.001. (B) Expression and
localisation of EpCAM, CD117 in ascites-derived tumor cells in response to paclitaxel, CYT387 and a combination of paclitaxel+CYT387 treatment
was evaluated and quantified by immunofluorescence as described in Figure 1. Images are representative of three independent experiments
using three independent patient ascites samples. Significant intergroup variations are indicated by *P <0.05, **P < 0.01. (C) The expression and
localisation of embryonic stem cell markers NANOG and Oct4 in ascites-derived tumor cells was evaluated and quantified as described in Figure 1.
Significant variations between the groups are indicated by *P <0.05, **P<0.01. Magnification 200x; scale bar = 10 μM.
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http://www.biomedcentral.com/1471-2407/14/317period of only 27% [3]. This is mainly due to the escape
of a certain population of cells from the cytotoxic effect
of therapies during treatment. These residual cells re-
populate after a short duration (6–20 months), resulting
in an aggressive recurrent tumor which consequently
leads to patient’s mortality [2]. We have recently demon-
strated that a short-term single treatment of ovarian
cancer cells with cisplatin or paclitaxel resulted in re-
sidual cells with CSC-like trait capable of generating a
significantly greater tumor burden in mice than control
untreated cells [45]. In the current study, we demon-
strate similar CSC-like trait in in vitro paclitaxel treatedFigure 9 Effect of CYT387 on the proliferation of HEY cells and ascites-d
and combination of CYT387 and paclitaxel for three days. [3H]-thymidine was
data is a representation of three independent experiments performed in tripli
(B) Ascites-derived tumor cells obtained from three independent patients
was performed as described in the Materials. The data is a representation
ascites samples. Significant variations between the groups are indicated bisolated ascites derived tumor cells with concomitant
activation of the JAK2/STAT3 pathway. Using the HEY
cell line model in vivo, we demonstrate suppression of
paclitaxel treatment-induced tumor burden in mice by
CYT387 a potent JAK2-specific inhibitor. This effect of
CYT387 was mediated by substantially suppressing the
phosphorylation of STAT3 at Tyr-705 in vitro and
in vivo. This proof of principle study is the first to re-
port that targeting the activated STAT3 induced by
chemotherapy in vitro not only results in the abrogation
of CSCs in vitro but also in vivo, and that this correlates
with the reduction of tumor burden in mice. These dataerived tumor cells. (A) HEY cells were treated with paclitaxel, CYT387
added and the cells were harvested as described in the Materials. The
cate. Significant variations between the groups are indicated by *P <0.05.
were treated as described in Figure 9A. [3H]-thymidine uptake assay
of three independent experiments performed in triplicate on three
y *P <0.05, ***P < 0.001.
Figure 10 Tumor burden in mice injected with control, paclitaxel, CYT387 and combination of paclitaxel plus CYT387-treated cells.
Total tumor burden obtained from mice 6 weeks after ip injection of control, paclitaxel-treated, paclitaxel plus CYT387-treated and combination
of both CYT387 and paclitaxel-treated HEY cells (n = 5/group). 5×106 cells were inoculated in each case. *P < 0.05, significant increase in tumor
burden in paclitaxel-treated HEY cell derived tumors compared to control untreated group; and paclitaxel-treated HEY cell derived tumors to
paclitaxel plus CYT387-treated cell derived tumors. Images represent tumors debulked from one mouse in each group.
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JAK2/STAT3 pathway, ovarian CSCs and tumor burden
in in vivo mouse models has not been demonstrated
before.
After the first description of stem cells in ovarian tu-
mors nearly eight years ago [24], significant progress
has been made towards identifying, characterizing and
understanding CSCs and their role in ovarian cancer
[32,47,48]. However, despite these advances, ovarian
cancer patients are still faced with incurable chemore-
sistant disease that may be attributed to a population
of CSC-like cells [34]. In this study, using tumor cells
isolated from the ascites of recurrent ovarian cancer
patients we demonstrate that the emergence of a CSC-
like phenotype in response to a short-term paclitaxel
treatment in vitro coincided with enhanced staining of
β-tubulin III and ERCC1, indicative of an acquired re-
sistance to chemotherapy [49,50]. Enhanced expression
of β-tubulin isotype III and/or ERCC1 are known to be
expressed in tumor samples resistant to platinum and/
or taxane-based therapies [49-51]. In addition, samples
from advanced-stage ovarian cancer patients who de-
veloped clinical paclitaxel resistance showed increases
in several β-tubulin subtypes including β-tubulin sub-
type III [10]. The fact that the ascites derived tumor
cells used in this study not only showed significant
enhancement in the expression of β-tubulin isotype III
but also significant increase in the expression ofERCC1 in response to paclitaxel treatment, suggests
that the cells surviving paclitaxel treatment may also
had an elevated DNA repair mechanisms (genotoxic
stress). This phenomenon may have been attributed to
enhanced endogenous ERCC1 levels from previous
exposure to carboplatin in vivo (in patients) before
in vitro paclitaxel treatment of the isolated tumor cells
(Table 1, Ascites 1–3).
An analysis of known CSC markers (CD117 and
EpCAM) and embryonic stem cell markers (Oct4 and
NANOG) at the protein and mRNA levels in seven
ascites-derived tumor samples revealed enhanced ex-
pression of all tested CSC markers in response to
in vitro paclitaxel treatment. This increase of CSC and
embryonic stem cell markers in response to a short-
term paclitaxel treatment shown in this study mirrors
the response of HEY and OVCA 433 cell lines to pacli-
taxel treatment described previously [45]. The enhanced
expression of a CSC-like phenotype in ascites-derived
tumor cells coincided with the activation of the JAK2/
STAT3 pathway.
In this study we also demonstrate a similar enhanced
activation of the JAK2/STAT3 pathway in HEY cells
within 2–3 days in response to paclitaxel treatment.
Various cytokines and growth factors, including the gp130
family of cytokines that includes IL-6 and G-CSF, have
been shown to activate the JAK2/STAT3 pathway [52].
Activated JAK2 auto-phosphorylates its receptors, and
Figure 11 (See legend on next page.)
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Figure 11 Expression of P-JAK2, T-JAK2, P-STAT3 and T-STAT3 in mouse tumors generated from ip transplantation of control,
paclitaxel, CYT387 and combination of paclitaxel plus CYT387- treated HEY cells. (A) Immunohistochemistry staining of tumor sections for
the expression of P-JAK2 and T-JAK2 was performed as described in Materials. Quantification of staining was obtained as described in Materials
by using three independent xenografts. Significant variations between the groups are indicated by **P<0.01. (B) Tumor sections were stained for
P-STAT3 and T-STAT3 and quantification of the data was obtained as described in Figure 11A. Significant variations between the groups are
indicated by **P<0.01. Magnification 200×, scale bar = 10 μm
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http://www.biomedcentral.com/1471-2407/14/317additionally phosphorylates STAT3, which results in the
dimerization and translocation of STAT3 into the nucleus,
where it binds to specific regulatory sequences to activate
or repress transcription of target genes [37]. Recent stud-
ies have shown an acute drug-induced secretory response
in tumor cells [53,54]. This results in the autocrine secre-
tion of cytokines, which acts in favour of the tumor cells,
and has a negative impact on the therapeutic response
in patients [55,56]. We have also recently demonstrated
enhanced autocrine secretion of IL-6 and G-CSF by
HEY cells in response to paclitaxel-treatment in vitro
[47]. This suggests that autocrine effects of IL-6 and G-
CSF may activate the JAK2/STAT3 pathway in response
to paclitaxel-treatment in HEY cells. The enhanced activa-
tion of JAK2/STAT3 may be required for the enhance-
ment of CSC-like characteristics. This is evidenced by the
suppression of JAK2/STAT3 activation and significantly
suppressed expression of CSC markers at the mRNA level
in vitro after the addition of CYT387 with paclitaxel to the
HEY cell line. These effects of CYT387 resulted in the
inhibition of proliferation of paclitaxel-treated residual
ascites-derived tumor and HEY cells by a further ~40-90%.
The link between activation of the JAK2/STAT3 path-
way and CSCs has been shown in a previous study on
ovarian cancer, where the stem cell marker CD44 coupled
with the embryonic stem cell marker NANOG have been
linked with the activation of STAT3 in ovarian cancer cells
[57]. Such activation of STAT3 in these cancer cells re-
sulted in the expression of multidrug resistant genes and
concomitant chemoresistance. These studies are consist-
ent with reports demonstrating the STAT3 pathway to be
a requisite for the proliferation and maintenance of glio-
blastoma stem cells [58], as well as rapidly cycling intes-
tinal stem cells [59]. In addition, LIF and IL-6 mediated
STAT3 dependent regulation of the Oct4-NANOG cir-
cuitry has been shown to be necessary to maintain the
pluripotent inner cell mass, the source of embryonic stem
cells [60]. These studies suggest a close relationship be-
tween the cytokine-mediated activation of the JAK2/
STAT3 pathway and the survival of normal, cancer and
embryonic stem cells. The activation of the JAK2/STAT3
pathway by paclitaxel in the current study may facilitate
resistance to apoptotic pressures in paclitaxel-surviving
cells, thus pushing the residuals cells into adopting a che-
moresistant phenotype. This property of the activation of
JAK2/STAT3 pathway in response to chemotherapy is notunique to the HEY cell line but has also been observed
in tumor cells isolated from the ascites of ovarian cancer
patients and OVCA 433 ovarian cancer cell line [13].
We and others have previously shown constitutive ac-
tivation of STAT3 in high-grade ovarian carcinomas
and suppression of the growth of ovarian cancer cells by
inhibition of constitutive STAT3 activity [36,38]. Tyro-
sine phosphorylation of STAT3 has been considered to
be more important than serine phosphorylation for the
activation of STAT3 under oncogenic conditions [61].
Recent studies have demonstrated apoptosis, anchorage
independent death and potentiating effects of chemo-
therapy response in ovarian cancer cells by inhibiting
constitutively active STAT3 pathway [62]. This is consist-
ent with a recent gene expression analysis of matched
ovarian tumors and peritoneal metastasis which identified
enrichment of genes of the JAK/STAT pathway in peri-
toneal metastasis [63]. However, ours is the first study
that demonstrates that chemotherapy can induce early
activation of the JAK2/STAT3 pathway above the levels
normally present in cancer cells. As we show in this
study, this phenomenon is crucial for the survival of
chemotherapy-resistant CSCs which potentially are the
drivers of repopulation and the eventual recurrent disease.
The novelty of the present study is the demonstration
of the suppression of enhanced CSC-like characteristics
observed in ovarian cancer cells after a single dose of pac-
litaxel treatment by CYT387 in vitro, and the retention of
these characteristics in in vivo mouse xenografts. Tumor
cells within the xenografts generated from paclitaxel and
CYT387-treated cells had a lower proliferative potential
as evaluated by low Ki67 staining, and a smaller tumor
burden within the same time frame as that of the tu-
mors derived from paclitaxel-treated cells. In addition,
tumors derived from CYT387 and paclitaxel-derived
cancer cells had a lower expression of CA125. Elevated
level of CA125 is the hallmark of ovarian cancer diagno-
sis and frequently observed in recurrent disease [1,3].
CA125 expression has been shown to regulate the growth,
tumorigenesis and metastasis of ovarian cancer cells as
knock down of CA125 (deleted N-terminal region) com-
pletely abrogated the subcutaneous tumor forming ability
of SKOV3 cells in nude mice [64]. Conversely, the same
study showed that ectopic expression of CA125 with in-
tact cytoplasmic tail enhanced ovarian tumor growth and
metastases in SCID mice and the increased invasiveness of
Figure 12 (See legend on next page.)
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Figure 12 Expression of CSC markers and CA125 in mouse tumors generated from ip transplantation of control, paclitaxel, CYT387
and combination of paclitaxel and CYT387-treated HEY cells. (A) Immunohistochemistry staining of tumor sections for the expression of
Oct4, CD117 and CA125 was performed as described in Figure 11A. (B) Quantification of Oct4, CD117 and CA125 staining was obtained as
described in Figure 11A. Significant variations between the groups are indicated by *P<0.05 and **P<0.01. Magnification 200×, scale bar = 10 μm.
(C) The mRNA expression of EpCAM, CD44, CD117 and Oct4 in control, paclitaxel, CYT387 and paclitaxel plus CYT387-treated HEY cells-derived
xenografts was performed by q-PCR as described in the Methods section. The resultant mRNA levels were normalised to 18S mRNA. The experiments
were performed using four independent samples in triplicate. Significant intergroup variations are indicated by *P <0.05, **P<0.01.
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phenomenon (decreased expression of E-cadherin and
increased expression of N-cadherin and vimentin) of
the transfected cells in vitro. These findings provide
evidence that CA125 plays a critical role in ovarian
cancer cell growth, tumorigenesis and metastases. The
relatively lower abundance of proliferative and tumori-
genic markers in tumors derived from HEY cells treated
with CYT387 and paclitaxel compared to paclitaxel-
treated cells derived tumors suggest a crucial role of the
JAK2/STAT3 pathway in maintaining chemotherapy-
induced CSC phenotype in ovarian cancer. The fact that
these characteristics induced by paclitaxel and CYT387
can be translated from in vitro to in vivo mouse xeno-
grafts suggest that these phenotypes once embedded in
cancer cells becomes an intrinsic phenotype of the
tumor cells and can be retained in vivo.Figure 13 A model of chemoresistance and associated recurrence in
diagnosis, majority of the ovarian cancer patients present with high-grade
CSCs. After the first line of ‘traditional chemotherapy’ treatment majority of
mainly consist of chemoresistant CSCs with enhanced level of phosphoryla
recurrence, patients present with larger tumor burden which has increased
are treated with subsequent lines of chemotherapy (which differs in patien
mortality. However, if the patients are treated with ‘traditional chemotherap
during the first line of treatment, and/or subsequent lines of treatments. T
disease free survival period and better treatment outcomes.No significant differences in the invasion pattern were
observed between control untreated, paclitaxel-treated,
CYT387-treated and paclitaxel plus CYT387-treated cells-
derived xenografts. This may be due to the small number
of tumor xenografts analyzed or the fact that the cells only
received a single short-term dose of paclitaxel and/or
CYT387 treatments before inoculation into mice. Such
short-term treatments even if induced invasiveness (if any)
in vitro was not sustained during the six week tumor de-
velopment in in vivo microenvironment. In future studies,
this aspect of the work will be further investigated by
systemic administration of paclitaxel and/or CYT387 in
mice intraperitoneally inoculated with ovarian cancer
cells. This is likely to show differences in the invasion
pattern imposed by paclitaxel and/or CYT387 in vivo.
Repopulation of ovarian cancer cells that escape the
cytotoxic effects of first line of chemotherapy has anovarian cancer. Adapted from Googleimages, Wisegeek.com. At
tumors and associated ascites which contains tumor cells as well as
the tumor cells are eradicated leaving behind residual tumors which
ted JAK2/STAT3. These patients are in remission for 6–22 months. At
numbers of CSCs. Under the current treatment protocol most patients
ts), resulting in successive recurrences which ultimately leads to patient
y’ in combination with JAK2/STAT3 inhibitors, this will eradicate CSCs
his consequently may result in decreased tumor burden with increased
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ovarian cancer patients who do not receive treatment
for a short period (6–22 months) while in remission
after surgery and first line of chemotherapy [4]. During
this time it is hypothesized that the residual tumor
cells may have ample time to adapt to the changed
microenvironment, repopulate and progress the dis-
ease to a symptomatic state. Generation of CSC-like
characteristics in response to cytotoxic pressures may
be one of the important pathways by which chemona-
ive ovarian cancer cells escape the cytotoxic effects of
first line chemotherapy, adapt to the changed abdominal
microenvironment and repopulate over time to develop a
recurrent disease [47]. Our results firmly establish that
the taxane chemotherapy treatment activates the JAK2/
STAT3 pathway in ovarian cancer cells and isolated
tumor cells from ascites. We have also demonstrated
that CYT387 not only inhibits JAK2/STAT3 signaling
but also the expression of paclitaxel-induced CSCs that
subsequently results in reduced tumor burden in mice.
Our results provide strong evidence that CYT387 po-
tentiates these effects not only in vitro but also in vivo.
Taken together, the findings from this study lend sup-
port to further investigation into the use of CYT387 in
combination with chemotherapy (paclitaxel) for the bet-
ter management of ovarian cancer patients. Prospective
events demonstrating the activation of JAK2/STAT3
pathway and the involvement of residual CSC-like cells
in response to chemotherapy treatment, which are the
ultimate source of recurrent disease, are depicted in
Figure 13.
Additional files
Additional file 1: Figure S1. mRNA expression of CSC markers in
control and paclitaxel treated ascites-derived tumor cells. RNA from the
control and matching paclitaxel treated ascites-derived tumour cells was
extracted cDNA was prepared and q-PCR for EpCAM, NANOG CD44,
CD117, Oct4, JAGGED, STAT3 and E-cadherin was performed as described
in the Methods. The resultant mRNA levels were normalized to 18S mRNA.
The experiments were performed using five independent patient samples;
the resulting mRNA results were then pooled for analysis. Significant
variation is indicated by *P < 0.05.
Additional file 2: Figure S2. (A-B): Immunohistochemistry expression
of Ki67, cytokeratin 7 (CK7) in mouse tumors generated from ip
transplantation of control, paclitaxel, CYT387 and combination of CYT387
and paclitaxel-treated HEY cells. (A) Tumor sections were stained and
scoring for the staining of Ki67 and CK7 was performed as described in
Figure 11. Magnification 200X, scale bar = 10 μm. (B) Significant variations
between the groups is indicated by **P < 0.01.
Additional file 3: Figure S3. H and E staining of control and treated
HEY cell derived-tumor associated infiltrated organs in mice. 5 × 106 cells
were injected ip in each mouse. Histological images of liver and pancreas
showing infiltration of control, paclitaxel-treated, CYT387 and combination
of paclitaxel and CYT387-treated HEY cells. Arrows indicate tumor cells
invading the respective organs. Magnification 200×, scale bar = 10 μm.
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